DRIVER MUTATIONS IN MELANOMA

SNJEŽANA RAMIĆ and MELITA PERIĆ BALJA

Department of Oncological Pathology, ‘Ljudevit Jurak’ University Department of Pathology, Sestre milosrdnice University Hospital Center, Ilica 197, Zagreb, Croatia

Summary

In this review, we present the findings from the literature on several new molecules that can be targeted in the melanoma treatment process, especially metastatic melanoma, since five-year survival rates are below 20%. Recently, melanoma has been defined by mutations that occur in oncogenes and lead to melanomagenesis. A mutation in BRAF gene selects the patients for targeting therapy with BRAF inhibitors. Although BRAF inhibitor therapy is associated with clinical benefit, the majority of patients with the BRAFV600-mutated metastatic melanoma develop resistance, usually within the first year. Clinically significant discrepancy in BRAF status, between primary melanoma and its metastasis were detected in about 15% of cases. There are no specific recommendations on BRAF re-testing, but might be clinically relevant to repeat testing on recent metastatic sites in cases of previous BRAF wild type results.

KEY WORDS: metastatic melanoma, BRAF, p53, signaling pathway, mutations

INTRODUCTION

Melanoma is a malignant tumor of melanocytes (MM). Melanoma development correlates with the DNA damage caused by ultraviolet light (UV). In recent years the melanoma rate is increasing, probably due to increased unprotected exposure to UV radiation from either the sun or a variety of tanning devices. Apart sun exposure, older age, Caucasian raise or pre-existing moles, some genetic disorders increase the risk of melanoma (1).
Melanoma early stage, histologically is referred as the radial growth phase of melanocytes, spreading in the papillary dermis in depth less than 1 mm (Clark 2, Breslow 1). Deeper invasion of melanoma in the papillary dermis, referring as vertical growth phase, enables melanoma reaching the blood vessels and spreading to other parts of the body. Early stage melanoma often is cured surgically; otherwise, the treatment of choice is traditional cytotoxic chemotherapy, targeted therapies, and immune-based therapies (2). Metastatic melanoma (MM) treatment, with 5-year survival rate less than 20% due to resistance to standard chemotherapy, still remains a challenge (2). Although, MM is classified according to histology (Clark, Breslow, TNM), recently is defined by mutations that occur in oncogenes and lead to melanogenesis.

Physiological condition

The melanocytes physiological role is producing the pigment melanin that protects the body from the sunlight damaging effect. UV light damages the DNA directly and indirectly. Direct damage occurs when DNA absorbs UV photons, resulting in thymine-thymine dimers while indirect damage occurs via production of reactive oxygen radicals that can cause single-strand DNA breaks, or oxidize the nucleobases (3,4). If unprepared, aforementioned damages can cause inaccurate synthesis during DNA replication or repair, leading to mutations (4).

Sunlight damages keratocyanes positioned in the upper layers of skin, activating the DNA damage repair mechanism via p53 protein and also induce signalling towards the melanocytes to produce the melanin (3). Short-term sunlight exposure results in changed distribution of melanin granules (melanosomes) from the melanocytes to keratinocytes. Long-term tanning increase pigmentation by melanocytes modulation through keratinocytes signaling (1,3). Keratinocytes excrete alpha-melanocyte stimulating hormone (aMSH) which binds to the melanocortin-1 receptor (MC1R) on the surface of the melanocyte, activates microphthalmia associated transcription factor (MITF) and induces the production of melanin (4,5). On chronically sun-damaged skin, keratinocytes modulates melanocytes over c-KIT receptor signaling and activation of the RAS-RAF-MEK-ERK pathway (MAPK), which is crucial in melanocyte development and proliferation. RAS proteins can activate the MAPK pathway (involved in cell differentiation and proliferation) or the PI3K/AKT/mTOR pathway (involved in cell survival) (4,5). Somatic mutations in these pathways are the main driver of malignancy.

Mutation events

A mutation of tumor suppressor gene TP53 is one of the earliest events in melanocytes caused by UV radiation, resulting in non-functional p53 protein, detected in over 40% of melanomas (6,7). Viros and colleagues showed that induction of TP53 mutation, or its inactivation, accelerate BRAF-driven melanogenesis (6). Functional p53 protein is a major regulator of cell cycle arrest during sun-damaged DNA repair or p53 induced apoptosis (6,7). Conventional chemotherapy usually targets p53 function, but melanomas are resistant to p53 dependent apoptosis, which might be a reason for melanoma resistance to chemotherapy (8). According to Terzian et al. increased p53 can prevent progression of nevi to melanoma and specific activation of p53 might be an effective strategy to reduce the risk of melanoma (7).

BRAF mutation is one of the early events in malignant transformation of melanocytes. Still, it is considered that single mutation is not sufficient
to induce melanoma, since BRAFV600 mutations are frequently found in benign and dysplastic melanocytic nevi (9). Thus, the NCCN Clinical Practice Guidelines in Oncology (2017) do not recommend the BRAF mutation testing of primary cutaneous melanoma, unless required for systemic therapy (2). UV-induced mutations, as loss of function in tumor suppressor gene phosphatase and tensin homolog, PTEN (found in 40-60% of melanomas), mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A) (found in ~40% of melanomas) and over-expression of MDM4 protein (found in ~60% of melanomas), both acting as a negative regulator of p53 protein, were also described (1,3,4).

**BRAF mutations**

The BRAF gene encodes a protein which plays a role in the control of cell proliferation, differentiation, inflammatory responses and apoptosis via the mitogen activated protein kinase (MAPK) pathway (10). Mutations of BRAF gene have been found in ~60% of all MM and the most prevalent mutations are located on codon 600 of the BRAF gene. The most common BRAFV600E mutation is the result of a transversion of thymine to adenine at nucleotide 1799 (T1799A), and subsequently a substitution of valine (V) for glutamic acid (E) in position 600 of BRAF protein. Less common substitutions are of V for lysine (V600K (~8–20%)), arginine (V600R (1%)), leucine (V600M (0.3%)), and aspartic acid (V600D (0.1%)). Some nonV600 mutations (K601E, D594N) are also found in a low percentage of patients, but till today without known clinical significance. RAF mutation results in constitutive activation of the MAPK signaling pathway (10,11).

Patients with the detected BRAFV600 mutation are candidates for the BRAF inhibitor therapy with vemurafenib and dabrafenib, that become an important step forward in the treatment of melanomas (9,12). Although BRAF inhibitor therapy is associated with clinical benefit, the majority of patients with the BRAFV600 mutated MM develop resistance to vemurafenib, usually within the first year. Mechanisms of resistance to the BRAF inhibitors might be acquired by amplification or mutations in other genes evolved in the same pathways. Amplification of BRAF, CRAF, insulin-like growth factor 1 receptor (IGF1R), hepatocyte growth factor (HGF), and platelet-derived growth factor receptor (PDGFRβ), and mutations in NRAS, MEK1, NF1 and PI3KCA genes were detected. As Shi and colleagues reported, 70% of the resistance is acquired through the MAPK reactivation. NRAS mutations were detected in 18%, KRAS in 7% and BRAF amplification or alternative splicing were detected in more than 40% of melanoma resistant to BRAF inhibitors (12).

The majority of tumors are heterogeneous, which has recently been confirmed in melanomas. The molecular profile of MM can change over time, and the amount of mutations increase with progression (13). Furthermore, some mutually exclusive mutations (eg. BRAF and NRAS) can be present in the same tumor due to its clonal heterogeneity (13,14). Recently, discrepancy in BRAF mutation between primary melanoma and metastases and between different metastatic sites of recurrent melanoma has been documented. Yancovitz et al. detected discordant BRAF status among two metastases of the same patients in 26% and between primary melanoma and a metastasis in 33% (15). Heinzerling analyzed up to 13 tumour samples per patient and found discordant results in 18.9% of patients while discordance between primary tumours and metastases was detected in 44% of patients (16). Yet, Hannah et al. found discordance between primary melanoma and brain metastasis in only 14% of cases (17). Meta-analysis performed by Valachis and Ullenhag detected discrepancy in BRAF status between primary and metastatic lesions in 13.4% and between two metastatic lesions in 7.3% of cases (18). Meta-analysis by Grzywa and colleagues found overall heterogeneity in 8.1% of melanomas and 16% heterogeneity in BRAF-mutated melanomas. They also recorded discrepancy in BRAF status between primary and metastatic lesions in 15.5% of cases (19).

Other driver mutations

MEK1 (MAP2K1) is a central mediator in the MAPK signaling pathway. Somatic mutations in MEK1 have been found in 6–7% of MM and often occur together with BRAF or NRAS mutations.
The MEK inhibitor therapy (trametinib and cobimetinib) is used for the treatment of BRAFV600E-mutated melanoma resistant to BRAF inhibitors. Mutations in NRAS have been found in ~13–25% of all MM with the result of constitutive activation of the MAPK pathway. Our pilot study detected NRAS mutations in over 60% of BRAF wild type metastatic melanomas (not published), namely a substitution of glutamine to arginine/lysine/leucine at position 61 (Q61R/K/L). NRAS mutations might respond to MEK inhibitor-based therapy (1,3,10,11).

Mutations in G proteins (GNA11 and GNAQ) have been found in up to 2.3% of all MM. Expression of G proteins results in melanocyte transformation and increased signaling through the MAPK pathway (1,3,10,11).

Neurofibromin 1 (NF1) is a tumor suppressor gene that suppresses the function of the RAS protein. NF1 mutations occur in 11.9% of MM. Inactivation or loss of NF1 function might play a role in melanomagenesis. NF1 mutations might be responsible for resistance to RAF/MEK targeted therapies. Currently, there is no therapy directed to G-proteins or NF1 (1,3,10,11).

C-KIT (CD117) is a receptor tyrosine kinase that activates the PI3K pathway, the MAPK pathway, and other pathways involved in mediating pro-growth and pro-survival signaling. Mutations or amplification of KIT gene has been found in 3–9% of all MM. Phase II clinical trials have demonstrated clinical responses of c-KIT-mutated melanoma to imatinib, sunitinib, sorafenib, and nilotinib, and everolimus after acquiring resistance to imatinib (1,3,10,11).

The CTNNB1 gene encodes the β-catenin that regulates cell growth and adhesion of epithelial cells regulated via glycogen synthase kinase 3 beta (GSK3β). Somatic mutations in CTNNB1 have been found in 2–7% of MM. Concurrent mutations in β-catenin and NRAS act synergistic in promoting melanoma formation (1,3,10,11).

Several other amplifications (MITF, MYC, AKT3), and mutations in genes (AT-rich interactive domain-containing protein 2 (ARID2), protein phosphatase 6 (PPP6C), sorting nexin 31 (SNX31), rac family small GTPase 1 (RAC1); serine/threonine kinase 19 (STK19), and transforming acidic coiled-coil-containing protein 1 (TACC1)) were discovered recently, that might be a potential target in melanoma therapy (1,3,10,11).

**CONCLUSION**

Clinically significant discrepancy in BRAF status, between primary melanoma and its metastasis, is reported in about 15% of cases. There are no specific recommendations about BRAF retesting, although repeating testing on recent metastatic sites might be clinically relevant, especially in cases of previous BRAF wild type results. Despite the fact that changes in melanoma cells occur during progression, there is no additional testing recommendations till today. Recent literature, discovered many potential targets for developing a specific therapy, of which we presented the most promising one.

**REFERENCES**


Corresponding author: Snježana Ramić, Department of Oncological Pathology, ‘Ljudevit Jurak’ University Department of Pathology, Sestre milosrdnice University Hospital Center, Ilica 197, Zagreb, Croatia. e-mail: snjezana.ramic@zg.t-com.hr